01872nas a2200241   4500008003900000245008400039210006900123260000800192300001100200490000700211520124800218100001101466700001301477700001201490700001301502700001301515700001201528700001101540700001201551700001101563700001101574856004501585       2019                          d00aEvaluation and Application of Donors with Primary Central Nervous System Tumors0 aEvaluation and Application of Donors with Primary Central Nervou  cOct  ae136770 v333 aBackground: This study aimed to explore the safety of donors with primary central nervous system tumors for kidney and liver transplantations.

Methodology: Clinical data of 29 donors with primary CNS tumors in January 2007 to December 2017, as well as the follow-up data of 16 liver transplant recipients and 46 kidney transplant recipients, were analyzed. According to the risk factors, the high-risk group was classified as Group 1, the low-risk factors were classified as Group 2, and the unknown risk group was classified as Group 3. The incidence of donor-transmitted CNS tumors was calculated and compared.

Results: The duration from the diagnosis of 29 donors to donation was 5.67 ± 6.36 months. None of the liver and kidney transplant recipients who were followed up had tumor metastasis. Although the mean survival time of Group 1 was lower than that of Group 2 and Group 3, the Kaplan-Meier curve showed no significant difference in survival time.

Conclusion: No obvious difference was observed between high-risk and low-risk and unknown risk CNS tumors in terms of the survival rate of transplants and tumor metastasis rate. High-risk CNS tumor donors can be used with the informed consent of recipients after a full evaluation.1 aWu, JH1 aQiao, PF1 aSun, XY1 aDong, JH1 aLiao, JX1 aLiu, XY1 aGao, Z1 aLan, LG1 aLi, HB1 aSu, QD  uhttp://613633.bywedr.asia/reference/4892